Stock Ticker

  • Loading stock data...

New Developments: Seadrill (SDRL), QUALCOMM (QCOM), GlaxoSmithKline (GSK)

Boston, MA 09/24/2014 (wallstreetpr) – Seadrill Ltd (NYSE:SDRL) saw one of its significant investors increasing his stake in the $13.13 billion offshore drilling business. Billionaire, John Fredriksen, bought 2 million more shares in Seadrill (SDRL) through his investment vehicle known as Hemen Holding Ltd. The latest acquisition brings his stake in the company to 115.1 million shares, which reflects about 23.34% ownership in the business. Seadrill Ltd (NYSE:SDRL) has been facing a number of challenges that include the uncertainty over its $4.25 billion deal in Russia because of the international sanctions against Moscow. The exit of a longtime adviser from the Seadrill Ltd (NYSE:SDRL) also raised concerns about its future.

QUALCOMM, Inc. (NASDAQ:QCOM) is gradually shifting its attention away from smartphones. The company concedes that the market is slowing down because of saturation and competition. China has also become a problem for QUALCOMM (QCOM) as it was recently under investigations over antitrust claims. While QUALCOMM, Inc. (NASDAQ:QCOM) intends to maintain its leading position in the smartphone chip market, the company believes that the future lies in enabling connectivity on a wide range of devices. The company seeks to bring capabilities such as wireless charging, communication, computer vision and more, to devices such as wearables, washing machines and others. That is what QUALCOMM, Inc. (NASDAQ:QCOM) executives are fond of calling “The Internet of Everything”, which is a big growth opportunity.

GlaxoSmithKline plc (ADR) (NYSE:GSK)‘s management is under fire because of what some investors term “erosion” of the business in key markets. The markets that are cited as increasingly challenging for GSK are China and the U.S. The company not only faces increasing competition in those markets, but it has also been slapped with huge fines to settle corruption claims. GlaxoSmithKline (GSK) was recently hit with a $489 million fine in China over claims that it paid bribes to doctors and hospitals to boost sales. GlaxoSmithKline plc (ADR) (NYSE:GSK)’s chairman, Chris Gent, is expected to leave the $114 billion drug company by the end of next year. However, some investors think his exit should be accelerated. In fact, others also want the CEO, Andrew Witty, to follow suit so that the company can chart a new path to recovery.

Published by Steve Hackney

Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.

Recent Stories

SignUp Now For Our Featured Newsletter